Literature DB >> 28602777

Ascending role of next-generation ALK inhibitors.

Daniel B Costa1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28602777     DOI： 10.1016/S1470-2045(17)30338-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.

Authors:  Xiuning Le; Deepa Rangachari; Daniel B Costa
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 2.  Treating ALK-positive non-small cell lung cancer.

Authors:  Dimitrios C Ziogas; Anna Tsiara; Georgios Tsironis; Maria Lykka; Michalis Liontos; Aristotelis Bamias; Meletios-Athanasios Dimopoulos
Journal:  Ann Transl Med       Date:  2018-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.